NEWARK, Delaware (March 06, 2014) – QPS Holdings, LLC, a leading full-service contract research organization, has won a CRO Leadership Award from Life Science Leader for ranking in the top 20th percentile in all five award categories: Quality, Innovation, Productivity, Reliability, and Regulatory.
“I am pleased and proud of QPS employees for consistently delivering the highest grade of discovery, preclinical and clinical drug development services. Their exceptional performance and dedication are underscored by this CRO Leadership Award,” said Ben Chien, PhD, QPS President and CEO.
The CRO Leadership Awards are based on marketing intelligence from Nice Insight, which specializes in market research on the outsourcing practices of pharmaceutical and biotechnology companies. Over 10,000 pharmaceutical and biopharmaceutical executives participated in Nice Insight’s annual survey. Respondents participate willingly so that their opinions may be heard, and with the understanding that pooled customer perceptions of individual CROs throughout the industry can facilitate the selection of future CRO partners.
“At Life Science Leader, we think having data-driven awards is more objective and valuable than having those awarded as a result of a nomination and voting process. The winners should be proud of these awards because they were determined by data gathered from customers,” shared Rob Wright, Editor in Chief, Life Science Leader.
Dr. Chien notes, “I’m thrilled because the CRO Leadership Awards purely reflect the opinions of people who count – pharmaceutical and biopharmaceutical customers who buy CRO services. Through passionate and productive work, we strive to create value for patients and customers, while creating opportunities for our employees to grow and thrive in a friendly and caring company environment. This CRO Leadership Award is another testimony that we are well-positioned to succeed in realizing our corporate vision: to become a global leader in contract research.”
QPS is a GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, preclinical, and clinical drug development services. Since 1995, it has rapidly expanded from a boutique bioanalysis shop to a full-service CRO with over 1,100 employees in the US, Europe, India and Asia Pacific. Today, it offers expanded pharmaceutical contract R&D services with special expertise in Neuropharmacology, DMPK, Toxicology, Bioanalysis, Translational Medicine, and Early & Late Phase Clinical Research.
Numerous acquisitions have strengthened QPS’ preclinical, early and late phase drug development capabilities worldwide. Added units – Toxicology in Taiwan and Neuropharmacology in Austria – have bolstered QPS’ preclinical services. Expansion of QPS’ Phase I Clinic in the Netherlands and the acquisition of Miami Research Associates (MRA), the largest multi-specialty clinical research center in the United States, have increased QPS’ ability to meet growing early phase clinical market demands. Additions in Taiwan, China, and Austria have increased QPS’ late phase clinical capabilities and enlarged its Asia Pacific and European presence, enabling the company to participate in the enrollment of global late phase clinical trials with new drug candidates for diverse therapeutic areas.
Through continual enhancements in capacities and resources, QPS stands tall in its commitment to deliver superior quality, skilled performance and trusted service to its valued customers. For more information, please visit: http://www.qps.com